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Abstract
Treatment options for those suffering from Parkinson’s Disease are as diverse as its symptoms.With the advent of modern
technology there are new and innovative treatments that are becoming available, such as Deep Brain Stimulation (DBS).
Prior to exploring treatment options one must t understand the various causes of the disease. Treatment of the various
motor and non-motor symptoms can include a combination of medication and surgical therapies.Among surgical interventions DBS is the treatment of choice. It has the fewest side effects and provides the greatest symptomatic relief.
Introduction
Parkinson’s disease was first formally written about in 1817, by
a prestigious English doctor, James Parkinson. He published a
short pamphlet about the disease titled, “An Essay on Shaking
Palsy”. In the beginning of his paper he describes the symptoms
of the disease as “involuntary tremulous motion, with lessened
muscular power parts not in action and even when supported;
with a propensity to bend, with trunk forwards and to pass
from a walking to running pace; the senses and intellect being
uninjured”. (Elis, 2013) Parkinson was not the one who discovered the disease as there are sources referencing the disease
dating back to the ancient Egypt and Mesopotamia. (Raudino,
2012) As time, technology, and science advanced, scientists and
medical professionals were able to further understand the causes and symptoms of the disease. Treatment options for those
suffering from Parkinson’s are as diverse as its symptoms. With
the advent of modern technology, there are new and innovative treatments that are becoming available. One of these new
treatments is Deep Brain Stimulation (DBS). As with all new
treatments, one has to assess its effectiveness, its side effects
and how it compares with old methods of treatment.This paper
will address these issues in relation to DBS and its treatment
for Parkinson’s disease.

Methods
This systematic review was composed after reviewing relevant
journal articles about the subject matter.Articles used discussed
causes of the disease, current treatment methods and alternative surgical interventions. Articles were obtained using search
engines like Proquest and MedLine and articles from published
journals.

Background
Prior to exploring treatment options, one must thoroughly
understand the disease and its causes. Parkinson’s has many
different causes, some rooted in genetics, others in chemical
imbalances. The genetic cause for this disease has been shown
to include five different genes. (Pchelina, et. al. 2014) The first of
these genetic proteins is ⍺-synuclein, a neuronal protein which
serves an unknown function. These proteins aggregate in the
Lewy bodies, causing researchers to conclude that they play
a major role in the protein composition of the Lewy bodies.

Although mutations within ⍺-synuclein are relatively rare; even
patients with sporadic PD seem to exhibit protein aggregates in
the Lewy bodies, leading researchers to believe that ⍺-synuclein
plays a major role in both genetic and sporadic forms of PD.
Several independent family studies done on groups of people
with PD show that ⍺-synuclein mutations are a rare cause of
PD. The largest analyses done on ⍺-synuclein and PD indicated
that allele length variability is associated with an increased risk
for PD. (Pihlstrøm, Toft, 2011).
Mutations in the gene encoding parkin, a 465 amino acid chain
protein is one of the causes of autosomal recessive PD. Parkin
mutations in familial PD suggest that the ubiquitin-protease system has an important role in the disease. (Pickrel,Youle, 2015)
Mitochondrial abnormalities are also thought to cause the disease. These abnormalities lead to a failure of cellular energy
production and increased free radicals. The newest gene discovered which confirmed these hypotheses is the PINK1 gene.
(Pickrel,Youle, 2015).
Another gene associated with Parkinson’s is the DJ-1 protein.
Although its exact function is unknown, it is thought to help
with proper protein folding. DJ-1 protein may be linked to abnormalities in the protein control system. Other studies show
that DJ-1 mutations may lead to increased levels of oxidative
stress. (Pchelina, et. al. 2014).
PD is not caused by genetic factors, although genetic factors
increase one’s risk for developing the disorder. Sporadic PD
is when there are multiple genetic alterations which increase
the risk of developing PD, but they do not cause PD. One such
risk factor is prevalent among Ashkenazi Jews carrying the GBA
gene mutation. Those who do have a GBA mutation are seven
times more likely to develop the disease when compared to
healthy control groups. (Feany, 2004).
The most common cause for PD is from the progressive loss
of dopaminergic neurons in the substantia nigra pars compacta. Motor symptoms appear when approximately 50%–60% of
these neurons degenerate, causing a 70%–80% depletion of dopamine levels in the dorsal striatum. (Pickrel,Youle, 2015).
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Discussion
Parkinson’s disease is associated with a wide variety of symptoms, both motor and non-motor. The four cardinal motor
symptoms associated with the disease are; Rest tremor, bradykinesia, rigidity and loss of postural reflexes. The rest tremors
seen in PD are usually found in the distal extremities, but they
can also be seen in the lips, chin and jaw. Bradykinesia can be
described as slow movement and it is a hallmark of basal ganglia
disorders. Although Parkinson’s patients seem to have impaired
motor programes, when provided an external stimulus many of
them exhibit normal movement. This phenomenon is known as
kinesia paradoxica. Rigidity is often one of the first symptoms of
the disease, but it is often misdiagnosed as arthritis or bursitis.
Neck and trunk rigidity leads to postural deformities. Additional
postural issues include, extreme neck flexion, trunk flexion and/
or scoliosis. (Jankovic, 2008).
Non-motor symptoms associated with the disease include;
autonomic dysfunction, cognitive abnormalities and sleep
issues, among others. Autonomic dysfunction features can include, orthostatic hypotension, sweating dysfunction, sphincter dysfunction and erectile dysfunction. Neurocognitive
dysfunction was tested on 537 PD patients using the
Neuropsychiatric Inventory. Eighty-nine per cent of patients
exhibited symptoms for at least one of the Neuropsychiatric
Inventory. The results of the Neuropsychiatric Inventory
were as follows: Fifty-eight percent of patients showed symptoms of depression, 54% showed apathy symptoms, 49%
exhibited anxiety symptoms and 44% showed signs of hallucinations. (Jankovic, 2008).
Sleep abnormalities often seen in PD were thought to be a side
effect of the medications patients were given. More recently,
some physicians are beginning to view it as a part of the disease.
Researchers began looking at the hypothalamic hypocretin system, a system that regulates sleep/wake cycles, to see how this
system differs in Parkinson’s patients. They have found that patients with PD had almost 50% fewer hypocretin neurons than
the healthy control group. (Fronczek, et. al. 2007).
There are no known preventions that will stop PD, however
there are some substances which have an inverse relationship
with PD. Caffeine has been found to reduce one’s risk for PD.
MPTP, one of the toxins associated with PD was injected onto
the striatum of mice. This led to an 85% decrease in dopamine
levels in the area. However when the mice were given moderate
amounts of caffeine, there was only a 60% decrease in dopamine
levels. This study leads to the conclusion that caffeine may help
mitigate some of the symptoms of PD, however this relationship
is not causal. (Holden, 2001).
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Nicotine, found in cigarettes, decreases the risk for developing the disease. It also inhibits the MPTP pathway, ensuring that
more dopamine receptors remain intact. Additionally, nicotine
has been shown to reduce the activity of Monoamine Oxidase,
which causes the oxidation of dopamine. Coffee drinkers have a
30% decreased risk of developing PD, while smokers have greater than a 30% reduction risk. (Martyn, Gale, 2003).
There is no known cure for Parkinson’s Disease, however,
there are a full array of medications and treatments to slow
progression of the disease and to relieve some of its symptoms,
both motor and non-motor. Drug therapy is the mainstay of
treatment. Surgical intervention, such as deep brain stimulation is recommended in severe cases. Physiotherapy, speech
therapy and occupational therapy have all been shown to help
Parkinson’s patients as well, particularly in advanced stages of
the disease. (Rajput, Rajput, 2006).
The three main drugs being given to Parkinson’s patients are,
Levodopa, monoamine oxidase B (MAO-B) inhibitors and dopamine agonists (DAs). MAO-B inhibitors are given to patients
with mild motor symptoms, usually in the early stages of the
disease. When administered in conjunction with Rasagiline, patients dropped 3-4 points on the Unified Parkinson’s Disease
Rating Scale. When taken with other drugs, such as SSRIs,
some patients began exhibiting serotonin syndrome symptoms.
Dopamine Antagonists act directly on striatal dopamine receptors and have a greater effect on motor symptoms than MAO-B
inhibitors. DAs are often prescribed as a first order treatment
in patients who are young at age of onset. Side effects of DAs
include; nausea, headaches, sleep attacks and Impulsive Control
Disorder, among others. DAs are usually supplemented with
levodopa in the later stages of PD. Levodopa, also known as the
gold standard in PD treatment, is the first order treatment given
to elderly Parkinson’s patients. Levodopa is most successful at
eliminating PD motor symptoms, however, it has many side effects. (Sprenger, Poewe, 2013).
Some side effects of levodopa include nausea and dyskinesia.
Being on the drug long-term causes up to ⅓ of patients to develop dyskinesias. Between doses patients can experience painful muscle spasms and the reemergence of other PD symptoms.
The National Health Service of England recommends keeping
the dose of levodopa as low as possible to prevent motor complications. The Movement Disorder Society recommends taking
levodopa with a DA to prevent long-term motor side effects.
(LeWitt, 2008).
The most common surgical intervention for Parkinson’s patients
is Deep Brain Stimulation (DBS). Prior to the discovery of this
treatment, surgical treatment for movement disorders involved
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ablations. More specifically pallidotomy, thalamotomy, and more
recently, subthalamatomies. Thalamotomy relieved many of the
tremors and dopa-induced dyskinesia, however it often left patients with speech and cognitive deficiencies. Unilateral pallidotomy have been shown to significantly improve contralateral
tremor, rigidity, bradykinesia, and dyskinesias. Side effect of pallidotomy include, weight gain, reduction in verbal fluency, and a
higher incidence of recurrent depression in patients who have a
prior history of the disease. Appropriate anatomical and careful
physiological screening prior to placement of the lesions may
decrease incidences of cognitive or neuropsychological damage.
Subthalamatomies have been experimented with as a cheaper
alternative to DBS. Preliminary findings indicate that there are
fewer cognitive and speech side effects than in pallidotomy and
thalamotomy. However postoperative chorea occurred in more
than half of patients who underwent this procedure. This remains a concern with subthalamotomy. Additional research is
necessary to ascertain whether this treatment is a viable alternative to DBS. (Walter,Vitek, 2004).
Deep brain stimulation is a highly effective surgical therapy
for PD and other movement disorders (fig. 1). To qualify as a

Once a patient is found to be a viable candidate for surgery,
they undergo basic preliminary testing. The main test involves
a patient skipping a dose of levodopa at night. The patient then
goes to the neurologist so he can assess the patient’s symptoms without medication. Afterwards, the patient then takes
his dose of levodopa, so the neurologist can see how it affects
the patient’s symptoms. Symptoms that do not improve with
medication, usually will not improve with DBS either, hence the
significance of this test (Farris, Giroux, 2011).
Once cleared for surgery the patient will undergo the procedure. The procedure involves the implantation of electrodes
in the subthalamic nucleus, two lead coated wires and a neurostimulator, which is technologically similar to a pacemaker.
(Farris, Giroux, 2011) Prior to the implantation of the electrodes, patients undergo stereotactic imaging to locate the
subthalamic nucleus. Surgery for implantation of electrode and
lead is usually done under local anesthesia, so the surgeon can
determine the best location for the electrode within the subthalamic nucleus. Using microelectrodes, the surgeon will stimulate different areas to figure out where the patient will have the
greatest symptomatic relief. Once the best tract is found the
surgeon will replace the microelectrodes with the lead through
various means. After this is done, the patient is closed up and
the second part of the procedure takes place at a later date.
(Benabid, et. al. 2009).
The second part of the procedure involves placing the neurostimulator in the subcutaneous pouch in the subclavicular area.
This is done under general anesthesia. Once the neurostimulator is inserted and connected to the lead, the programming of
the stimulator begins. Programming of the neurostimulator will
usually begin a week after surgery.Voltage is increased gradually,
while the patient is tested by the neurologist. Once an appropriate setting has been found for the patient, PD medication dosages are lowered to prevent dyskinesias. (Benabid, et. al. 2009).

Figure 1.This drawing depicts the components of DBS
candidate for surgery, patients must be first undergo testing
by a competent neuropsychologist and neurologist. A neurologist will review the patient’s medical history and ensure that
reasonable medical intervention has been applied. The patient
will then meet with a neuropsychologist to discuss goals and
expectations of the surgery. If a patient has unrealistic expectations, they are no longer an appropriate candidate for surgery.
(Benabid, et. al. 2009).

Deep brain stimulation offers many advantages to ablations,
although it is not a risk-free procedure. When performing
ablations, the lesions placed on the brain are permanent and
irreversible. With DBS, the neurostimulator can be turned off,
or reprogrammed in case of complications. In cases of adverse
effects, the neurostimulator can even be explanted. Some of
the adverse effects of the implantation of the electrodes and
leads in DBS include hemorrhaging, seizures and/or infection.
Although these side effects are relatively rare (4%), it is important to know about them. With regard to the neurostimulator,
battery depletion is an issue. Batteries have a median life of four
years, but in patients with high voltage stimulation, they may last
only one year. (Grill, 2005).
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Studies done on the short and long term effects of the procedure on Parkinson symptoms show significant improvement
in many of them. Following DBS of the subthalamic nucleus,
levodopa dosages decreased on average 55.9%. Rigidity and
bradykinesia symptoms decreased by 63% and 52% respectively
after twelve months. Parkinsonian tremors decreased by 61%
following subthalamic nucleus DBS. However, stimulation targeting the dorsal border of the subthalamic nucleus produced
an 86% improvement in tremor symptoms. Gait and balance
issues caused by PD are less likely to be helped by DBS. In a
one year follow up study, patients were found to have the same
gait and balance scores as their preoperative scores with drug
treatment. (Fasano, et. Al. 2012).
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